By Chris Wack
Landos Biopharma shares were up 10% to $4.31 after the company published positive safety, tolerability, pharmacokinetic and clinical efficacy results from its NX-13 Phase 1b trial in patients with ulcerative colitis in the Journal of Crohn’s and Colitis.
The stock closed Monday’s session down 5%, and is up 79% in the past 12…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
Read the full article here